tiprankstipranks
In this article:
Blurbs

Mizuho Securities Sticks to Its Buy Rating for IN8bio (INAB)

In this article:
In this article:

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on IN8bio (INABResearch Report) today and set a price target of $12.00. The company’s shares closed last Thursday at $4.00.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 11.5% and a 41.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Currently, the analyst consensus on IN8bio is a Moderate Buy with an average price target of $12.00.

See today’s best-performing stocks on TipRanks >>

Based on IN8bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.39 million. In comparison, last year the company had a GAAP net loss of $1.68 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

Read More on INAB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed